Sodium polystyrene sulfonate and insulin were used as therapeutic agents for hyperkalemia at a level of 5.00–5.50 mmol/L, and prescriptions of insulin increased rapidly beginning at a serum potassium level of 5.75–6.0 mmol/L. This evidence concerns the gene INS and Hyperkalemia.